NASDAQ:ACHL Achilles Therapeutics (ACHL) Stock Price, News & Analysis $1.08 0.00 (0.00%) (As of 11/29/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Achilles Therapeutics Stock (NASDAQ:ACHL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Achilles Therapeutics alerts:Sign Up Key Stats Today's Range$1.05▼$1.0850-Day Range$0.95▼$1.0852-Week Range$0.63▼$1.76Volume22,605 shsAverage Volume446,790 shsMarket Capitalization$44.18 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company OverviewAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Read More… "Start Earning Extra Income with Just $30" (Ad)What if you could unlock a steady income stream from stocks priced under $30? Our new guide walks you through simple, effective options strategies designed for everyday investors. With step-by-step insights, you’ll learn how to transform familiar names like Ford and Intel into reliable monthly income generators.Claim Your Free Report Now: “Options Made Simple – 2 Affordable Stocks for Monthly Income” Achilles Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks48th Percentile Overall ScoreACHL MarketRank™: Achilles Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 626th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAchilles Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAchilles Therapeutics has received no research coverage in the past 90 days.Read more about Achilles Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Achilles Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achilles Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achilles Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchilles Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.57% of the float of Achilles Therapeutics has been sold short.Short Interest Ratio / Days to CoverAchilles Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achilles Therapeutics has recently increased by 35.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAchilles Therapeutics does not currently pay a dividend.Dividend GrowthAchilles Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.57% of the float of Achilles Therapeutics has been sold short.Short Interest Ratio / Days to CoverAchilles Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achilles Therapeutics has recently increased by 35.40%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.91 News SentimentAchilles Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Achilles Therapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Achilles Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.38% of the stock of Achilles Therapeutics is held by insiders.Percentage Held by Institutions56.38% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Achilles Therapeutics' insider trading history. Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHL Stock News HeadlinesAchilles Therapeutics PLC: Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketNovember 19, 2024 | finanznachrichten.deAchilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketNovember 19, 2024 | globenewswire.comEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.November 30, 2024 | ProsperityPub (Ad)Achilles Therapeutics PLC: Achilles Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | finanznachrichten.deAchilles Therapeutics reports Q3 EPS (48c) vs. (42c) last yearNovember 14, 2024 | markets.businessinsider.comAchilles Therapeutics Explores Strategic Options Amid Financial UpdateNovember 14, 2024 | markets.businessinsider.comAchilles Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Edge Higher in Monday TradingSeptember 24, 2024 | msn.comSee More Headlines ACHL Stock Analysis - Frequently Asked Questions How have ACHL shares performed this year? Achilles Therapeutics' stock was trading at $0.8890 at the start of the year. Since then, ACHL shares have increased by 20.9% and is now trading at $1.0750. View the best growth stocks for 2024 here. How were Achilles Therapeutics' earnings last quarter? Achilles Therapeutics plc (NASDAQ:ACHL) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.41) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.41). When did Achilles Therapeutics IPO? Achilles Therapeutics (ACHL) raised $176 million in an initial public offering (IPO) on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO. Who are Achilles Therapeutics' major shareholders? Top institutional shareholders of Achilles Therapeutics include BML Capital Management LLC (9.98%). How do I buy shares of Achilles Therapeutics? Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Achilles Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA). Company Calendar Last Earnings8/14/2024Today11/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACHL CUSIPN/A CIK1830749 Webwww.achillestx.com Phone44-0-20-8154-4600FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+272.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.45% Return on Assets-47.68% Debt Debt-to-Equity RatioN/A Current Ratio6.04 Quick Ratio6.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.51 per share Price / Book0.43Miscellaneous Outstanding Shares41,100,000Free Float38,889,000Market Cap$44.18 million OptionableNot Optionable Beta1.35 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ACHL) was last updated on 11/30/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredBlack Friday ONLY — must read!Legendary financial forecaster, Martin Weiss just issued a chilling warning: He believes The Deep State rec...Weiss Ratings | SponsoredTrump’s “Magic Pattern” targets stock market boomAccording to millionaire-trader Jeff Clark, President Trump's bold agenda is poised to unleash a historic trad...InvestorPlace | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.